Hook & thesis
I remain a buyer of Cardinal Health (CAH) after digging through the numbers. The stock trades around $223.81 and while the headline P/E - roughly 30 - looks full relative to large-cap peers, the company's cash generation and low revenue multiple argue there is upside if management sustains margin discipline and specialty growth.
My base case: Cardinal's distribution scale and free cash flow allow it to absorb temporary revenue pressure from IRA pricing changes while continuing to pay a modest dividend and fund returns of capital. That combination supports a long trade with a clearly defined stop and a target near previous highs.
What Cardinal does and why the market should care
Cardinal Health is a global medical and pharmaceutical distributor serving hospitals, health systems, pharmacies and ambulatory centers. It operates two main segments: Pharmaceutical and Specialty Solutions, which moves branded and generic drugs and some specialty therapies, and Global Medical Products and Distribution, which supplies medical, surgical and laboratory products worldwide.
Why that matters: distribution is a scale game. Volume, tight logistics and service agreements are sticky revenue sources that generate sizeable free cash flow when executed well. Cardinal's reported free cash flow is $4.525B, and the company carries an enterprise value near $55.9B versus a market cap roughly $51.8B. That cash generation supports operational continuity through regulatory and pricing disruptions, and gives management flexibility to invest in automation, specialty services and margin-improvement programs.
Hard numbers backing the view
- Share price: $223.81 (current trading level).
- Market capitalization: about $51.8B.
- Reported earnings per share (annual): approximately $7.40, putting the trailing/near-term P/E in the ~30x area.
- Free cash flow: $4.525B - a material cash engine for buybacks, dividends and investment.
- Valuation metrics: price-to-sales ~0.2 and EV/EBITDA ~14.5.
- Dividend: quarterly payment of $0.5158 (next ex-dividend 10/01/2026; payable 10/15/2026), implying an annual run-rate near $2.06 and a yield just under 1% at current prices.
The revenue backdrop shows modest top-line growth expectations: near-term consensus revenue around $66.96B (up ~4.6% YoY on the referenced estimate). Management has flagged that IRA pricing changes will continue to create headwinds similar to prior years, but they explicitly expect to defend profitability through distribution agreements and operational efficiency programs.
Valuation framing
Valuation looks mixed. The P/E in the low-30s is not cheap for a distributor; many defensive distributors trade at lower multiples when growth is muted. But Price/Sales of 0.2 is low and highlights the company's enormous revenue base. EV/EBITDA at ~14.5 suggests the market is assigning a reasonable multiple to operating cash flow. In plain terms: the market is paying a premium to earnings but not to revenue, which suggests skepticism about margin durability rather than top-line exposure.
One structural complication is negative book-related ratios: Price-to-book is deeply negative owing to a negative book value calculation (share buybacks and returns of capital have reduced equity). That skews some accounting ratios (debt-to-equity is negative for the same reason). Use those metrics cautiously - the company's cash flow and enterprise multiples give a cleaner picture.
Technical & sentiment context
Technically the stock is below its 20/50-day SMAs (50-day ~ $232.46) and momentum indicators show some bearish tilt: RSI sits around 40 and MACD shows bearish momentum. Short interest data show modest short activity: recent short interest near ~6.7M shares with days-to-cover near 4.6 - not alarmingly high but notable. These factors mean the trade needs a disciplined stop.
Catalysts (2-5)
- Quarterly results that show margin resilience despite IRA pricing pressure - a beat/firmer guidance could re-rate the earnings multiple.
- Progress in specialty pharmacy and distribution agreements that shift revenue mix to higher-margin services.
- Operational efficiency and automation initiatives that materially improve EBITDA margins and support cash flow conversion.
- Share repurchase cadence and continued cash returns that support EPS even with sluggish top-line growth.
Trade plan (actionable)
| Entry | Target | Stop | Time horizon |
|---|---|---|---|
| $223.81 | $260.00 | $205.00 | Long term (180 trading days) |
Rationale: Enter at current levels ($223.81). The target $260 is near the stock's 52-week high ($258.30 on 08/11/2026) and represents upside if margins stabilize and specialty gains accelerate. The stop at $205 protects capital under a scenario where margin pressure and technical deterioration persist.
Why 180 trading days? That duration (about nine months) allows time for one full set of quarterly results, any incremental guidance updates, and the operational levers—automation, specialty scale—to begin showing contribution to margins and free cash flow. Shorter horizons risk noise from technical momentum without enough time for the fundamental recovery to play out.
Position sizing and risk-management notes
I categorize this trade as medium risk. Use position sizing that limits downside to a percentage of portfolio that you're comfortable losing if the stop is triggered. Reassess position after each quarterly release and if the stop is hit, step aside and re-evaluate on fresh fundamentals.
Risks and counterarguments
- IRA pricing pressure can accelerate. If pricing reforms deepen or accelerate beyond management expectations, revenue and margins could compress faster than forecast, undermining cash flow.
- High reported P/E relative to peers. The stock's P/E in the ~30x range implies the market expects margin stability or improvement; if margins weaken, the multiple could re-rate lower quickly.
- Negative book/equity metrics. Accounting oddities (negative price-to-book, negative debt-to-equity signs) reflect aggressive capital returns and complicate some valuation comparisons.
- Technical weakness. The stock sits below key moving averages and MACD is bearish; near-term technical selling could push price toward the stop before fundamentals reassert.
- Execution risk. Efficiency programs and specialty ramp-ups are not guaranteed; missed targets or lost distribution contracts would be a material negative.
Counterargument: Critics will point out the P/E as evidence the stock is priced for perfection and that continued IRA revenue headwinds make earnings growth unlikely. That's fair: if growth stalls and margins compress at the same time, the multiple can collapse. The counter to that is Cardinal's strong free cash flow and its operational levers: even with top-line pressure, the ability to convert sales to cash gives the company optionality to buy back shares, maintain the dividend and invest in higher-margin services. That optionality is what underpins my willingness to buy at $223.81 with a clear stop.
What would change my mind
- Sustained decline in free cash flow below $3B on a trailing basis without a credible operational recovery plan.
- Quarterly results with accelerating margin erosion and guidance that materially lowers revenue or EPS expectations for the year.
- Loss of large distribution agreements or evidence that specialty growth is stalling.
Conclusion
Cardinal Health is a scale distribution business with meaningful free cash flow and operational levers to protect profitability. That combination supports a long trade at current levels with disciplined risk control: entry $223.81, target $260.00, stop $205.00 and a horizon of long term (180 trading days). The trade is not without risk - valuation requires execution - but the company's cash generation and revenue base give me confidence that the downside is containable and the upside material if management delivers on specialty and efficiency initiatives.
Trade plan recap: Buy CAH at $223.81. Target $260.00. Stop $205.00. Time horizon: long term (180 trading days).
I'll update the stance after the next quarterly report or any material change to IRA-related guidance. For now, I'm still buying, but with my stop firmly in place.